Leora Horn

Leora Horn is a thoracic oncologist who led the CASPIAN trial comparing durvalumab with or without tremelimumab added to first-line chemotherapy in extensive-stage SCLC, demonstrating improved survival with durvalumab plus chemotherapy. Her research has broadly contributed to understanding immunotherapy predictive biomarkers in SCLC and other thoracic malignancies. She has published extensively on PD-L1 expression in SCLC, mechanisms of immune resistance, and clinical pharmacology of checkpoint inhibitors. She has mentored multiple thoracic oncology fellows and clinical investigators.